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Background: Leukemic B-cell precursor (BCP) lymphoblasts were identified as a novel
expression site for coagulation factor XIII subunit A (FXIII-A). Flow cytometry (FC) revealed
three distinct expression patterns, i.e., FXIII-A negative, FXIII-A dim, and FXIII-A bright
subgroups. The FXIII-A negative subgroup was significantly associated with the “B-other”
genetic category and had an unfavorable disease outcome.
Methods: RNA was extracted from bone marrow lymphoblasts of 42 pediatric patients
with BCP-acute lymphoblastic leukemia (ALL). FXIII-A expression was determined by
multiparameter FC. Genetic diagnosis was based on conventional cytogenetic method
and fluorescence in situ hybridization. Affymetrix GeneChip Human Primeview array
was used to analyze global expression pattern of 28,869 well-annotated genes.
Microarray data were analyzed by Genespring GX14.9.1 software. Gene Ontology
analysis was performed using Cytoscape 3.4.0 software with ClueGO application.
Selected differentially expressed genes were validated by RT-Q-PCR.
Results: We demonstrated, for the first time, the general expression of F13A1 gene
in pediatric BCP-ALL samples. The intensity of F13A1 expression corresponded to the
FXIII-A protein expression subgroups which defined three characteristic and distinct gene
expression signatures detected by Affymetrix oligonucleotide microarrays. Relative gene
expression intensity of ANGPTL2, EHMT1 FOXO1, HAP1, NUCKS1, NUP43, PIK3CG,
RAPGEF5, SEMA6A, SPIN1, TRH, and WASF2 followed the pattern of change in the
intensity of the expression of the F13A1 gene. Common enhancer elements of these
genes revealed by in silico analysis suggest that common transcription factors may
regulate the expression of these genes in a similar fashion. PLAC8 was downregulated in
the FXIII-A bright subgroup. Gene expression signature of the FXIII-A negative subgroup
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showed an overlap with the signature of “B-other” samples. DFFA, GIGYF1, GIGYF2,
and INTS3 were upregulated and CD3G was downregulated in the “B-other” subgroup.
Validated genes proved biologically and clinically relevant. We described differential
expression of genes not shown previously to be associated with pediatric BCP-ALL.
Conclusions: Gene expression signature according to FXIII-A protein expression status
defined three novel subgroups of pediatric BCP-ALL. Multiparameter FC appears to
be an easy-to-use and affordable method to help in selecting FXIII-A negative patients
who require a more elaborate and expensive molecular genetic investigation to design
precision treatment.
Keywords: pediatric BCP-ALL, FXIII-A, F13A1, gene expression signature, B-other genotype, oligonucleotide
microarray, RT-Q-PCR
INTRODUCTION
According to current knowledge, acute lymphoblastic leukemia
(ALL) can be best characterized by an integrated set of clinical,
pathological, morphologic, immunophenotypic, and genetic
properties. Detailed characterization of the neoplastic clones of
children with ALL allowed the development of highly effective
risk-tailored therapies. Introduction of advanced diagnostic tools
helped in identifying an increasing number of molecular targets
and may contribute to the application of personalized treatment
offering cure for each individual patient. Recurrent genetic
aberrations represent the basis of the classification of ALL
according to the 4th edition of theWHOClassification of Tumors
of Hematopoietic and Lymphoid Tissues in 2008, and its 2016
revision (1, 2). Gene expression profiling by oligonucleotide
microarray was shown to contribute to conventional and
molecular cytogenetics by improving diagnostic accuracy and
prognostic relevance as well as by defining new entities. The “B-
other” genetic subgroup, i.e., BCP-ALL cases without established
recurrent genetic abnormalities exhibits alterations to be revealed
by advanced genomic technologies. Within “B-other” ALL,
Philadelphia-like (Ph-like) or BCR-ABL1-like ALL, a provisional
entity of the 2016 revision of the WHO classification, has
been defined based on gene expression signature similar to Ph-
positive/BCR-ABL1-positive ALL and characteristically distinct
from the rest of BCP-ALL cases (“non-B-other”) (3–6). Recently,
fourteen B-cell precursor (BCP)-ALL subgroups were defined by
analyzing a large sample set of an international study using RNA-
sequencing. The study revealed six new subgroups in addition
to previously identified ones demonstrating the diagnostic utility
and prognostic power of gene expression studies in pediatric
BCP-ALL (7).
Our group identified BCP-ALL blasts as a new expression site
for coagulation factor XIII subunit A (FXIII-A). In contrast to the
BCP-ALL blasts, neither normal bone marrow B-cell progenitors,
nor mature B-cells, both normal and leukemic once, nor T-
lymphoblasts/lymphocytes express FXIII-A (8). We observed
three characteristic expression patterns by flow cytometry (FC):
FXIII-A negative, FXIII-A dim, and FXIII-A bright lymphoblasts
with about two thirds of pediatric BCP-ALL patients representing
FXIII-A positive (FXIII-A dim and bright) cases. According to
our retrospective clinical investigation, patients with FXIII-A
negative lymphoblasts had significantly worse event-free and
overall survival than patients with FXIII-A positive lymphoblasts.
Moreover, the “B-other” genetic subtype was significantly more
frequent within the FXIII-A negative than in the FXIII-A positive
subgroup (9). The prognostic importance of FXIII-A expression
by FC was confirmed and further specified in a recently
concluded prospective study suggesting a favorable prognostic
effect of the FXIII-A dim expression pattern within the FXIII-A
positive subgroup (unpublished results). Here we present results,
for the first time, on gene expression signatures associated with
the three characteristic FXIII-A protein expression patterns. In
addition, we investigated overlaps between the gene expression
profile of the FXIII-A negative protein expression subgroup with
the gene expression profile of the “B-other” subgroup.
MATERIALS AND METHODS
Patients
Samples were collected from pediatric patients with BCP-
ALL treated in four Hungarian Pediatric Hematology and
Oncology Departments (University of Debrecen, Debrecen;
Semmelweis University, Budapest; University of Pécs, Pécs;
BAZ Country Hospital and University Teaching Hospital,
Miskolc) between September 1, 2015 and August 31, 2018.
Patients were treated according to BFM ALL-IC 2009 clinical
trial (EuDraCT No: 2010-019722-13). Patients with BCR-ABL1
rearrangement [t(9, 22)] were excluded, since they were not treated
according to BFM ALL-IC 2009 protocol. Quantitatively and
qualitatively suitable RNA was separated from 42 patients with
FXIII-A negative (14), FXIII-A dim (21), and FXIII-A bright
(7) BCP-ALL.
Excess bone marrow (BM) samples were collected after
signed informed consent obtained from study participants and
their legal caregivers. The study was approved by the Scientific
Research Ethical Committee (“TUKEB”) of the Medical Research
Council of Hungary: No. 43033-1/2014/EUK(423/2014) and was
carried out according to the Code of Ethics of the World Medical
Association and the ethical standards of the 2000 Revision of the
Helsinki Declaration.
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Immunophenotype Analysis
The FXIII-A expression pattern was determined by
multiparameter FC analysis as published before (9). Bone
marrow samples were examined for the following antibody
combination: cytoplasmic FXIII-A(FITC)–CD10(PE)–
CD45(PerCP-Cy5.5)–CD19(APC)–CD19(PECY7). CD19, CD45
markers were purchased from Becton Dickinson Biosciences
(San Jose, CA, USA), CD10 marker were purchased from DAKO
(Glostrup, Denmark), CD19(PECY7) marker were purchased
from Sony Biotechnology (San Jose, CA, USA). Generation and
fluorescent isotihocyanate (FITC) labeling of mouse monoclonal
antibody against FXIII-A was carried out as previously described
(10). One-hundred thousand events were acquired with the
help of FacsCanto-II (Becton Dickinson Biosciences, San Jose,
CA, USA) and Navios (Beckman Coulter, Brea, CA, USA) flow
cytometers. According to the intensity of FXIII-A expression,
patients were assigned to three groups: BCP-ALL with FXIII-
A negative blasts (<20% FXIII-A positive lymphoblasts;
FXIII-A negative group), BCP-ALL with moderate FXIII-A
expression (20–79% FXIII-A positive lymphoblasts; FXIII-A
dim group), and BCP-ALL with strong FXIII-A expression
(≥80% FXIII-A positive lymphoblasts; FXIII-A bright group).
To determine FXIII-A expression of leukemic cells, normal
residual lymphocytes served as a negative control.
FC data were analyzed by FACSDiva (Becton Dickinson,
Franklin Lakes, NJ, USA) or Kaluza (Beckman Coulter, Brea,
CA, USA) softwares. Flow cytometers were subjected to daily
performance checks, using Cytometer Setup and Tracking
(Becton Dickinson, Franklin Lakes, NJ, USA) or Flow Check Pro
(Beckman Coulter, Brea, CA, USA) fluorescent microbeads.
Genetic Investigations
Cytogenetic analysis was performed on unstimulated 24 h
cultures of BM according to standard protocol. Fluorescence in
situ hybridization (FISH) was carried out on cells from the same
BM samples using commercially available probe sets (BCR-ABL,
ETV6-RUNX1, KMT2A). Patients with t(12, 21)/ETV6/RUNX1
or high hyperdiploidy (51–65 chromosome number) were
considered as low-risk group. The high-risk group consisted
of patients with KMT2A rearrangements, iAMP21, complex
karyotype, near haploidy (chromosome number 23–29), and
low hypodiploidy (chromosome number <45). Patients with
t(1, 19), and all other genetic subgroups not fitting in the low-
and high-risk categories, including the “B-other” subgroup were
considered as intermediate-risk group (6, 11).
RNA Preparation
Excess BM samples from BCP-ALL patients were collected into
PAXgene Blood RNA Plastic Tube (PreAnaltyX, Hombrechtikon,
Switzerland). Total cellular RNA was isolated using PAXgene
Blood miRNA Kit (PreAnalityX) according to conventional
protocol. Qualitative and quantitative analyses of RNA were
performed using Agilent Bioanalyzer (Agilent Technologies, La
Jolla, CA, USA). Samples with an RNA Integrity number above
8.0 were used in MicroArray analysis.
Microarray Analysis
Affymetrix GeneChip Human Primeview array (Affymetrix,
Santa Clara, CA, USA) was used to analyze global expression
pattern of 28,869 well-annotated genes. 3’IVT Expression Kit
(Affymetrix) and GeneChip WT Terminal Labeling and Control
Kit (Affymetrix) were used for amplifying and labeling 250
ng of RNA samples. Samples were hybridized at 45◦C for
16 h and then standard washing protocol was performed using
GeneChip Fluidics Station 450 (Affymetrix) and the arrays were
scanned on GeneChip Scanner 7G (Affymetrix) procedure. Data
of this study have been deposited in NCBI’s Gene Expression
Omnibus and are accessible through GEO Series accession
number GSE134480 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE134480).
Gene Ontology Analysis
Gene Ontology (GO) analysis was performed using Cytoscape
3.4.0 software (cytoscape.org) with ClueGO application. The
settings were the following: GO biological process and GO
immune system process. For statistical analysis two-sided
hypergeometric test and Benjamini-Hochberg FDR were used.
Significantly enriched GO categories were considered to p-value
<0.05 and κ score<0.4.
Real Time Quantitative Polymerase Chain
Reaction (RT-Q-PCR) Validation of
Microarray Data
For RT-Q-PCR validation of microarray data pre-designed,
factory-loaded 384-well TaqMan low-density array
(ThermoFisher Scientific, Waltham, MA, USA) was used
to determine the level of expression of selected genes using
technical duplicates. Genes for validation were selected based on
fold-changes (with fold-changes >2.0 cut-off) between any of
the pre-defined subgroups and based on putative biological and
clinical relevance of gene functions as defined by GO analysis
data (Table 1). RT-Q-PCR expression levels of target genes were
normalized to the mean of B2M, GAPDH, and GUSB reference
genes. Normalized gene expression values were calculated based
on the 1Ct method, where relative expression equals 2−1Ct,
where1Ct represents the threshold cycle (Ct) of the target minus
that of the mean of reference genes.
In silico Investigation of Validated DE
Genes
Interactions of validated genes and F13A1 gene were investigated
using STRING v11. (12) and GeneHancer (13) databases.
STRING v11 database contains putative protein-protein
interactions predicted on a well-defined score system.
GeneHancer portrays 285 000 integrated candidate enhancers
and subsequently links enhancers to genes.
Statistical Analysis
Microarray data were analyzed by Genespring GX14.9.1
software (Agilent Technologies, La Jolla, CA, USA). To
identify statistically significant genes, we used volcano
plot analysis. The resulting scatterplot showed statistical
significance (p-value) vs. magnitude of change (fold-change).
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TABLE 1 | Genes selected for validation by RT-Q-PCR based either on gene expression fold-changes detected by Affymetrix Microarray (in bold characters) or based on
selected GO annotations.
Genes selected for
validation
Fold changes detected by Affymetrix MicroArray GO annotations
FXIII-A negative/FXIII-A
dim
FXIII-A negative/FXIII-A
bright
FXIII-A bright/FXIII-A
dim
WASF2 0.94 0.50 0.53 Angiogenesis
BCL2L1 0.79 0.60 0.75 Apoptosis regulation
CASP2 0.90 0.79 0.88 Apoptosis regulation
DFFA 0.33 0.39 1.19 Apoptosis regulation
PAK2 1.91 1.07 0.56 Apoptosis regulation
PIK3CG 1.58 1.62 1.03 Apoptosis regulation
PKN2 1.43 1.26 0.88 Apoptosis regulation
SEMA6A 1.06 2.38 2.23 Apoptotic process
CLSTN1 0.51 0.45 0.88 Calcium ion binding
IL7R 1.03 0.98 0.94 Cell differentiation
PLAC8 1.30 1.33 1.02 Cell differentiation
RORA 0.92 1.01 1.10 Cell differentiation
NUCKS1 1.56 1.41 0.90 Cell differentiation
TRH 2.05 1.64 0.80 Cell-cell signaling
FOXO1 1.53 1.28 0.84 Cellular response to
glucocorticoid stimulus
CX3CR1 0.83 1.63 1.97 Chemokine receptor activity
EHMT1* 1.18 1.22 1.03 Chromatin modification
ING5* 0.97 1.25 1.29 Chromatin modification
JMJD1C 0.97 0.67 0.69 Chromatin modification
WAC 1.24 1.50 1.21 Chromatin modification
SART3 5.90 2.55 0.43 Chromatin modification
MDM2* 1.28 1.14 0.89 Identical protein binding
GIGYF1 3.84 5.07 1.32 Insulin-like growth factor receptor
signaling pathway
GIGYF2 1.08 1.06 0.98 Insulin-like growth factor receptor
signaling pathway
TAOK1 4.60 2.67 0.58 Kinase activity
SPIN1 1.28 1.27 0.99 Methylated histone binding
MAP4 1.29 1.19 0.92 Microtubule binding
AKAP13 1.14 1.16 1.02 Nuclear export
KHDRBS1 1.66 1.21 0.73 Nuclear export
MAGOH 1.35 1.25 0.92 Nuclear export
NUP43* 1.12 1.00 0.89 Nuclear export
ZC3H11A 12.64 3.37 0.27 Nuclear export
POLDIP3 1.60 1.48 0.92 Nuclear export
SRSF5 1.14 1.28 1.12 Nuclear export
FGFR1OP 7.20 2.50 0.35 Nuclear export
HAP1 1.07 0.86 0.80 Post-transcriptional regulation of
gene expression
F13A1 1.86 1.60 0.86 Protein-glutamine
gamma-glutamyltransferase
activity
CCL5 1.16 1.12 0.97 Protein homodimerization
CD3G 0.80 0.65 0.81 Protein heterodimerization
RAPGEF5 1.35 1.22 0.90 Ras signaling pathway
ANGPTL2 16.94 2.89 0.17 Signaling receptor binding
DHX36 0.83 0.80 0.96 Translation regulation
INTS3 17.71 3.41 0.19 Translation regulation
RC3H1 0.69 0.46 0.67 Translation regulation
SECISBP2L 1.45 1.54 1.06 Translation regulation
For definition of the three different FXIII-A expression groups see text.
Genes marked in * have also been listed under the GO term: peptidyl-lysine modification (GO:0018205).
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TABLE 2 | Clinical and pathological characterization of patiens with BCP-ALL.
Patient ID code Sex Age
(years)
Initial WBC
(G/L)
Ratio of FXIII-A
positive cells (%)
Genetic
category
Outcome
(dead/alive)
cALL_RNS_13 M 8 3.9 10.9 iAMP21 Dead
cALL_RNS_14 M 11 19 1.4 B-other Dead
cALL_RNS_15 M 3 5.9 5.1 B-other Alive
cALL_RNS_16 M 2 23.38 0.9 Hyperdiploid Dead
cALL_RNS_17 F 4 25.9 1.7 B-other Alive
cALL_RNS_26 M 0 8.33 2 Hyperdiploid Alive
cALL_RNS_33 F 12 22.6 5 B-other Alive
cALL_RNS_34 F 13 98.8 13 B-other Alive
cALL_RNS_35 M 2 10.45 1.8 ETV6/RUNX1 Alive
cALL_RNS_36 F 1 11.03 4 TCF3/PBX1 Alive
cALL_RNS_53 M 2 5.51 11.4 B-other Dead
cALL_RNS_54 F 3 18.33 8.4 B-other Dead
cALL_RNS_18 M 2 5.9 1.1 Hyperdiploid Alive
cALL_RNS_19 M 3 15.9 10.6 KMT2A Alive
cALL_RNS_45 F 1 11.37 28.8 B-other Dead
cALL_RNS_46 F 1 5.71 32.6 ETV6/RUNX1 Dead
cALL_RNS_47 M 0 377 23 KMT2A Alive
cALL_RNS_58 F 4 12.14 41 Hyperdiploid Alive
cALL_RNS_59 F 3 4.4 48.9 Hyperdiploid Alive
cALL_RNS_60 M 6 3.31 34.6 Hyperdiploid Alive
cALL_RNS_61 M 4 8.9 52 ETV6/RUNX1 Alive
cALL_RNS_62 F 2 21.91 71.9 Hyperdiploid Alive
cALL_RNS_63 M 3 3.62 45 ETV6/RUNX1 Alive
cALL_RNS_64 F 2 5.3 71.9 ETV6/RUNX1 Alive
cALL_RNS_44 M 8 19.73 76.8 Hyperdiploid Alive
cALL_RNS_50 M 3 7.28 59.6 B-other Alive
cALL_RNS_52 F 3 83.69 58 B-other Alive
cALL_RNS_55 F 2 12.34 56 Hyperdiploid Dead
cALL_RNS_56 M 12 10.5 24.9 B-other Dead
cALL_RNS_57 F 7 1.33 35.6 Hyperdiploid Alive
cALL_RNS_51 F 16 12.38 25 B-other Alive
cALL_RNS_49 M 2 14.5 22.4 B-other Alive
cALL_RNS_02 F 10 6.51 95 B-other Dead
cALL_RNS_03 F 15 5.64 72.5 Hyperdiploid Alive
cALL_RNS_04 F 5 5.1 69 ETV6/RUNX1 Alive
cALL_RNS_01 F 1 222.8 85 B-other Dead
cALL_RNS_05 F 12 19.54 95 ETV6/RUNX1 Alive
cALL_RNS_06 F 16 48.55 94 KMT2A Alive
cALL_RNS_07 F 5 61.6 88 ETV6/RUNX1 Alive
cALL_RNS_08 F 2 2.72 91 Hyperdiploid Alive
cALL_RNS_09 F 4 8.12 82.3 ETV6/RUNX1 Alive
cALL_RNS_37 M 16 20.1 98.9 Hyperdiploid Alive
Affymetrix data files were imported using the Robust Multi-
Array Average algorithm and median normalization was
performed. To identify differentially expressed genes between
pre-defined data sets, statistical analysis was performed using
ANOVA with Tukey post-hoc test (14) and moderated T-
test, Benjamini-Hochberg False Discovery Rate was used for
multiple testing corrections, p-value <0.05 was considered as
significant difference.
RESULTS
Characterization of Samples of Children
With BCP-ALL
RNA samples obtained from 42 pediatric patients with BCP-
ALL were used for gene expression profiling investigations
(Table 2). Cytoplasmic expression pattern of FXIII-A by FC
successfully divided patients into three categories: patients with
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FIGURE 1 | Representative dot plots and histograms of leukemic lymphoblasts. There are three different patterns of cytoplasmic FXIII-A expression in terms of
positivity of leukemic lymphoblasts: (A) negative expression pattern below 20%, (B) dim expression pattern between 20 and 80%, and (C) bright expression pattern
≥80% of leukemic lymphoblasts (black) with a FXIII-A staining exceeding the intensity of negative controls, i.e., residual normal lymphocytes (gray). Based on FXIII-A
expression intensity of normal residual lymphocytes, the threshold of positivity is marked by the dashed line on the respective dot-plots (upper quadrants). The
intensity of the FXIII-A expression increased continuously, as the histogram of lymphoblasts with dim expression pattern shows (B, lower quadrant), which excludes
the existence of a distinct FXIII-A negative and a FXIII-A bright sub-population.
FXIII-A negative, FXIII-A dim and FXIII-A bright BCP-ALL.
Representative FC dot plots and histograms are shown in
Figure 1. Regarding genetic categories, 27 patients had recurrent
genetic abnormalities and 15 patients were assigned to the “B-
other” subgroup: 7/12 FXIII-A negative patients, 6/21 FXIII-A
dim patients, and 2/7 FXIII-A bright patients.
Gene Expression Profiles of BCP-ALL
Samples
Differentially expressed (DE) genes were identified using two
distinctive features: FXIII-A protein expression determined by
FC and “B-other” status. DE genes were screened by volcano
plot filtering. There were 26 genes found when comparing the
FXIII-A negative with the FXIII-A bright subgroup. The FXIII-
A dim vs. bright comparison resulted in 155 DE genes and
there were 88 DE genes identified between the FXIII-A negative
and dim subgroups. With the exception of one to two outliers
within the respective groups, heat map analysis exhibited three
different patterns of gene expression for each, FXIII-A negative,
FXIII-A dim, and FXIII-A bright subgroup. Importantly, FXIII-
A negative and bright samples clustered close together and were
well-separated from the FXIII-A dim subgroup (Figure 2).
Comparing the gene expression signature of the “B-other”
subgroup with the rest of patient samples, the so called “non-
B-other” group, 142 DE genes were found after filtering to
1.5-fold-change. Heat map analysis clearly showed two distinct
sub-populations: gene expression signature of the “B-other”
subgroup differed characteristically from the gene expression
signature of the “non-B-other” subgroup (Figure 3). Then we
investigated how DE genes, characteristic for “B-other” status,
were related to DE genes of subgroups according to FXIII-A
expression pattern. We found 32 DE genes expressing exclusively
in the FXIII-A negative and “B-other” group vs. FXIII-A
negative and the “non-B-other” group. Heat map analysis
confirmed that, with the exception of one outlier, gene expression
profile characterizing FXIII-A negative samples overlapped with
gene expression profile characterizing samples of the “B-other”
subgroup (Figure 4).
Functional Characterization of
Differentially Expressed Genes in the
BCP-ALL Subgroups
Identification of enriched functional categories according to
the FXIII-A protein expression pattern, DE genes were
categorized into 156 GO processes. Nevertheless, most of
them, in particular those with the strongest statistical p-values,
were related to epigenetic and/or gene expression regulatory
processes such as histone modification, chromatin organization,
RNA destabilization, post-transcriptional regulation of gene
expression, etc., or other regulatory and cellular processes, such
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FIGURE 2 | Gene expression signatures according to FXIII-A protein expression; heat map analysis. With the exception of one to two outliers within the respective
groups, heat map analysis exhibited three different patterns of gene expression for each, FXIII-A negative (green color), FXIII-A dim (red color), and FXIII-A bright (blue
color) subgroups.
as apoptosis and morphogenesis (Supplementary Table 1). In
addition, we identified biological processes resulting in peptidyl-
lysine modification, which are in relation with the known
physiological function of FXIII-A catalyzing the formation of γ-
glutamyl-ε-lysyl amide crosslinks between fibrin monomers to
form an insoluble clot (Supplementary Table 1).
In the “B-other” status comparison of DE genes with a fold-
change >2.0, much less GO processes were identified than
according to the FXIII-A status comparison. Genes involved
in lymphocyte and T-cell apoptotic processes (CCL5, CD3G,
IL7R, PLAC8) were over-presented, as well as two others,
CX3CR1, RORA, corresponding to macrophage migration.
When decreasing the filtering threshold to fold-change >1.5,
additional biological processes proved significant represented
by the following genes, BCL10, CX3CR1, GNLY, PTPRC, STK4,
TNFSF10, ATP2B1, DNAJC3, PLAC8, THRA, MAPKBP1, PER1,
RORA, USP32, CCL5, GNG2, PLCB3, BCL10, CCL5, CD3G, IL7R
(Supplementary Table 2).
Validation of Global Transcriptomics Data
From the oligonucleotide microarray results of DE genes,
either according to FXIII-A expression status or according to
“B-other” genetic status we selected 45 genes for validation
by RT-Q-PCR. Selection of 13/45 genes was based on fold
change results, whereas an additional 32/45 genes were selected
according to enriched functional categories of potential interest
as defined by the GO analysis (Table 1). We were not able to
detect transcripts of RORA by RT-Q-PCR which might have a
technical reason.
FXIII-A Expression-Based Results
Expression of F13A1 gene was detected and readily validated
by RT-Q-PCR in every sample. Intensity of gene expression;
however, was characteristically different among samples of the
three different FXIII-A protein expression subgroups with an
increasing intensity in terms of relative fold-changes measured
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FIGURE 3 | Gene expression signatures according to “B-other” status; heat map analysis. Heat map analysis clearly showed two distinct sub-populations: gene
expression signature of the “B-other” subgroup (red color) differed characteristically from the gene expression signature of the rest of samples, the “non-B-other”
subgroup (green color).
by RT-Q-PCR from the FXIII-A negative, through dim to bright
subgroups (Figure 5).
Similarly, most of the genes (8/13 p < 0.05, 9/13 p <
0.10) from the group selected on the basis of highest fold
changes between any two groups among FXIII-A negative,
dim and bright groups according to the microarray results
were validated by RT-Q-PCR. Of the 25 genes selected on
basis of functional significance according to GO analysis,
four genes could be validated. Within the GO group of
translation regulation there were 2/6 with p < 0.05, and
3/6 with p < 0.10 (Table 3) genes that could be validated,
providing a considerably better ratio than it was found in the
subgroups of apoptosis regulation (0/3), chromatin modification
(1/5), and nuclear export (0/5) (Tables 1, 3). Generally, fold-
changes were enhanced in RT-Q-PCR compared to microarray
data (Supplementary Table 3). PLAC8 and HAP1 represent
impressive examples. DE of PLAC8, a placenta-specific gene of
unrevealed function, was not found significant by microarray
but turned out significant upon validation. HAP1, a member
of the translation regulation GO group, exhibited a very slight
overexpression by microarray and it proved much stronger
by RT-Q-PCR.
Considering individual normalized gene expression values, in
most of the cases, there was a clear trend of a continuous increase
from FXIII-A negative through dim to bright subgroups that
was endogenously validated by the F13A1 relative expression.
ANGPTL2, NUCKS1, RAPGEF5, and SEMA6A followed this
trend (Figure 5). Relative fold-changes were similar whether
determined by microarray measurements or RT-Q-PCR. In case
of FOXO1, HAP1, and TRH, separation of the bright subgroup
from the other two subgroups seemed more prominent and
showed a relatively higher fold-change value as determined by
RT-Q-PCR than compared to the microarray results. With the
exception of PLAC8, validated DE genes were downregulated
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FIGURE 4 | Overlap between the gene expression signatures of FXIII-A negative and “B-other” samples; heat map analysis. Heat map analysis confirmed that, except
for two outliers, gene expression profile characterizing FXIII-A negative samples overlapped with gene expression profile characterizing samples of the
“B-other” subgroup.
in the FXIII-A negative subgroup compared to the two other
subgroups (Supplementary Table 3).
Potential interactions could not be revealed between
the protein products of validated genes and FXIII-A using
STRING v11 functional protein association networks database.
Nevertheless, we could identify a FXIII-A dependent expression
of FOXO1. Using GeneHancer database we could in silico identify
enhancers that might have roles in the parallel upregulation
of F13A1 and validated genes. Transcription factor binding
sites of ATF7, POLR2A, RAD21, SMARCA5 gene products were
identified for all of the 14 genes shown in Table 3.
“B-OTHER” STATUS-BASED RESULTS
For the “B-other” status-based validation, DE genes related
to biological processes (macrophage migration, lymphocyte
apoptotic process, T cell apoptotic process, and their regulation),
were selected for validation, as GO analysis results were less
diverse than in the case of FXIII-A expression-based GO
annotations (Supplementary Table 1). We were able to validate
the differential expression of five genes by RT-Q-PCR. DFFA,
GIGYF1, GIGYF2, and INTS3were overexpressed in “B-other” vs.
“non-B-other” samples and in turn, CD3G exhibited a relatively
lower expression in the “B-other” vs. “non-B-other” samples
(Figure 6). RORA, IL7R, CCL5, PLAC8, CX3CR genes, selected
for validation based on their functions and fold-changes detected
by microarray, could not be validated.
DISCUSSION
FXIII-A is a useful marker of acute myeloid leukemia (AML)
of the monocyte and megakaryocyte lineages (31–34). However,
its expression in BCP-ALL blasts was an unexpected finding,
since, in contrast to the normal myeloid counterparts of AML
blasts, normal B-lymphocytes and their precursors do not express
FXIII-A (8). Intracellular expression of FXIII-A protein can be
consistently demonstrated in about two thirds of pediatric BCP-
ALL samples by FC. Interestingly, the FXIII-A negative status was
shown to be significantly associated with the “B-other” genetic
subtype and patients with FXIII-A negative BCP-ALL had a
significantly worse disease outcome than patients with FXIII-
A positive lymphoblasts (9). These facts together suggested that
pathological expression of FXIII-A in leukemic BCP blasts may
define one or more sub-populations according to the FXIII-A
expression pattern by FC.
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FIGURE 5 | Normalized gene expression values by RT-Q-PCR according to FXIII-A protein expression status; graph diagram. There was a continuous increase in
normalized gene expression levels from FXIII-A negative through dim to bright subgroups that was endogenously validated by the F13A1 differential expression within
the three FXIII-A protein expression groups. ANGPTL2, NUCKS1, RAPGEF5, and SEMA6A followed this trend. Based on the intensity of the differential expression,
separation of FOXO1, HAP1, and TRH genes of the FXIII-A bright subgroup were more prominent. PLAC8 expression was most intensive in the FXIII-A dim subgroup.
Little is known on the transcriptional regulation of the F13A1
gene. Molecular investigations of myeloid leukemia cell lines
revealed the presence of binding sites for ubiquitous (NF-1
and SP-1) and myeloid enriched (MZF-1-like protein, GATA-
1, and Ets-1) transcription factors in the promoter region of
the gene (35). Interestingly, transcription factor binding sites
for SP-1, GATA-1, and Ets-1 could not be confirmed by the
ENCODE ChIP-seq datasets (data not shown) (36). A more
recent study demonstrated that FXIII-A was synergistically
regulated by IL-4 and dexamethasone in alternatively activated
macrophages and these regulatorymolecules are relevant for both
normal and leukemic BCPs as well (37). However, transcriptional
regulation of the F13A1 gene in leukemic lymphoblasts has not
yet been studied.
Therefore, we decided to investigate the gene expression
profile of BCP lymphoblasts according to their FXIII-A
expression status. Preliminary results of an ongoing prospective,
multi-centric clinical study performed by our group suggested
the clinical relevance of the sub-populations characterized by
the FXIII-A expression pattern, since patients with FXIII-A
dim but not bright lymphoblasts had a better disease outcome
than patients with FXIII-A negative lymphoblasts (unpublished
preliminary results). Accordingly, we investigated the global gene
expression signature of three sample sets.
We have revealed that the three groups according to FXIII-
A expression pattern had unique gene expression signatures
which were characteristically different from each other. GO
analysis of data resulted in a number of biologically relevant
enriched functional categories. Identification of biological
processes resulting in peptidyl-lysine modification supported
the clinical relevance of our findings. FXIII-A is an enzyme
catalyzing the formation of γ-glutamyl-ε-lysyl amide crosslinks.
In addition to its well-known role in the formation of stable
fibrin clot, FXIII-A participates also in much less characterized
intracellular regulatory processes including differentiation of
monocyte/macrophages, osteoblast, and osteoclast (38). In
platelets, FXIII-A has been shown to crosslink cytoskeletal
proteins (39). Should FXIII-A participate in similar processes in
leukemic BCP lymphoblast, intracellular FXIII-A activity might
contribute to autophagy and apoptosis of FXIII-A expressing
lymphoblast. Moreover, the product of four genes validated
in our cohort, EHMT1, ING5, MDM2, NUP43 were shown
to methylate and acetylate lysyl groups of intranuclear and
intracellular proteins, among others, p53, and that way they can
regulate survival of neoplastic cells (25).
In addition, we showed that gene expression pattern of the
FXIII-A negative subgroup overlapped with the gene expression
profile of the “B-other” genetic subgroup. However, our results
indicated that the FXIII-A expression status was a more powerful
determinant of gene expression profile than the “B-other” status.
Fourteen genes were validated according to the FXIII-A
expression status. Importantly, we were able to detect the
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TABLE 3 | Relative expression, enriched functional categories according to GO annotations and clinical relevance of validated genes accordig to FXIII-A protein
expression patterns.
Gene Normalized fold-change by RT-Q-PCR GO annotations Clinical relevance in
leukemia and cancer
References
P-value* FXIII-A negative FXIII-A dim FXIII-A bright
ANGPTL2 0.0061 1.10E-03 6.47E-03 1.87E-02 Signaling receptor binding ETV6 target gene in pediatric
ALL
(15)
EHMT1 0.0401 4.79E-02 5.55E-02 8.89E-02 Chromatin modification Transcriptional coactivator
involved in
glucocorticoid-induced cell
death
(16)
F13A1 0.0013 5.58E-03 1.61E-02 4.02E-02 Protein-glutamine
gamma-glutamzltransferase
activitz
See article
FOXO1 0.0371 4.69E-02 3.56E-02 1.80E-01 Cellular response to
glucocorticoid stimulus
Key gene of the AKT/FOXO1
pathway involved in apoptosis
regulation of ALL blasts
(17–19)
HAP1 0.0016 1.10E-03 5.69E-03 1.94E-02 Post-transcriptional
regulation of gene
expression
Negative
asparaginase-resistance
biomarker in ALL
(20)
NUCKS1 0.0182 2.67E-01 2.59E-01 4.21E-01 Cell differentation Downregulated in VCR-resistant
ALL blasts
(21)
NUP43 0.0424 1.03E-02 1.17E-02 1.47E-02 Nuclear export W/o proven function in cancer
PIK3CG 0.0037 1.15E-01 1.24E-01 1.84E-01 Apoptosis regulation PIK3/AKT pathwayplays key
regulatory role in BCP-ALL
(22, 23)
PLAC8 0.0362 5.51E-03 8.20E-03 3.79E-03 Cell differentiation Gene of unknown function,
activated in various types of
mammalian and human cancer
(24, 25)
RAPGEF5 0.0192 1.36E-03 3.14E-03 8.01E-03 RAS signal pathway Abnormal expression involved in
papillary thyroid cancer
(26)
SEMA6A 0.0019 1.61E-02 2.78E-02 7.43E-02 Apoptotic process Overexpressed in ETV6/RUNX1
ALL
(27)
SPIN1 0.0077 1.35E-01 1.68E-01 2.76E-01 Chromatin organization Downregulation induces p53
activation in human cancer cells
(28)
TRH 0.0002 1.36E-03 5.09E-03 1.72E-02 Cell-cell signaling Deregulation implicated in
breast cancer
(29)
WASF2 0.0002 1.11E-01 1.55E-01 2.95E-01 Angiogenesis Recurrent WASF2/FGR fusions
are involved in suamous cell
cancer, cystadenocarcinoma,
and melanoma
(30)
*P-value of annova analysis comparing the FXIII-A negative, FXIII-A dim, FXIII-A bright groups.
expression of F13A1 gene in each individual sample, and the
intensity of F13A1 expression increased in parallel with the
increasing protein expression of FXIII-A among the three
subgroups. Of the 14 genes, ANGPTL2, EHMT1 FOXO1, HAP1,
NUCKS1, PIK3CG, RAPGEF5, SEMA6A, SPIN1, TRH, and
WASF2 have biologically and clinically relevant functions in
GO terms, and appear to have a role in leukemia and other
forms of cancer (Table 3). NUP43 has not yet been shown to
be associated with any forms of human cancer in contrast to
other members of the NUP gene family (40). PLAC8 which is a
trophoblast lineage marker physiologically, was most intensively
expressed in the FXIII-A dim subgroup. This gene has been
shown to be aberrantly activated in various types of cancer arising
in mammals and mammalian cancer cell lines, but not in any
subtype of human ALL (24, 25). Based on in silico investigations
we were not able to reveal a direct link between DE genes as
related to the three different FXIII-A expression groups and the
regulation of F13A1 gene. Common enhancer elements of the
validated DE genes and the F13A1 make likely that common
transcription factors may regulate the expression of these genes
in a similar fashion.
Validated DE genes of the “B-other” subgroup overlapping
with the gene expression profile of the FXIII-A negative
subgroup suggested the definition of a different sub-population
from the BCR-ABL1-like/Ph-like B-ALL subgroup discovered
originally by oligonucleotide microarrays (4, 5). Evaluating
the microarray results, we identified 14 DE genes in our “B-
other” subgroup (ANXA5, ARL4C, CD34, IFNGR1, MAGT1,
MAPKBP1, MAP3K2, ME3, OSBPL8, PAPOLA, PTPRC, SUZ12,
TACC1, TEMPO) overlapping with DE genes in the “B-other”
subgroup defined by Den Boer et al. (5). However, all the DE
genes within our “B-other” group differed from class-defining
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FIGURE 6 | Normalized gene expression values by RT-Q-PCR according to the “B-other” status; graph diagram. DFFA, GIGYF1, GIGYF2 and INTS3 genes were
overexpressed in “B-other” vs. “non-B-other” samples and in turn, CD3G exhibited a relatively lower expression in the “B-other” vs. “non-B-other” samples.
genes of the so called “novel” ALL subtype introduced by
Yeoh et al. (3) implying that they specify a different subtype.
Each validated gene in this category, i.e., CD3G, DFFA,
GIGYF1, GIGYF2, and INTS3 were shown to play a role in
neoplastic processes, including leukemia (41–45). However, none
of these genes were published previously to be associated with
pediatric BCP-ALL.
The small sample size and the low number of validated
genes due to restricted budget represent an important limitation
of the present study. The small number of patients involved
in this investigation would make a clinical outcome analysis
unreliable, even if statistically significant. Nevertheless, there was
a substantially larger ratio of children who died due to their
disease in the FXIII-A negative group: 5/14 children (36%),
than in the FXIII-A dim group: 5/21 (24%) and in the FXIII-A
bright group: 1/7 (14%). To investigate the clinical significance of
FXIII-A expression in children with BCP-ALL we have started
a pilot study of the ongoing BFM ALL-IC 2009 clinical trial
with the participation of the Hungarian, Polish and Slovak
national study groups. Preliminary analysis of this pilot study
confirmed the unfavorable outcome of patients with FXIII-A
negative BCP-ALL (results to be published upon completion
of the pilot study). Similarly, an exact relationship between
gene expression signature of FXIII-A negative samples and “B-
other” samples, including BCR-ABL1-like/Ph-like signature, can
be defined by investigating a larger number of samples from
children with BCP-ALL.
In conclusion, we were the first to demonstrate the general
expression of F13A1 gene in pediatric BCP-ALL samples. The
intensity of F13A1 expression corresponded to the expression
of FXIII-A protein, determined by FC in these samples. Three
well-defined categories of FXIII-A protein expression: FXIII-A
negative, FXIII-A dim, and FXIII-A bright subgroups defined
characteristic and distinct gene expression signatures detected
by Affymetrix oligonucleotide microarrays. Gene expression
signature of the FXIII-A negative subgroup showed an overlap
with that of the subgroup with “B-other” genetics. Validated
genes proved biologically and clinically relevant. We described
differential expression of genes not shown previously to be
associated with pediatric BCP-ALL. Protein products of the
newly identified genes may offer therapeutic targets for precision
treatment of BCP-ALL. Multiparameter FC appears to be an
easy-to-use and affordable method to assist in selecting pediatric
patients with FXIII-A negative BCP-ALL who require a more
elaborate and expensive molecular genetic investigation to design
individualized therapeutic protocols.
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